Multiple arrests in 'Operation Never Say Die,' targeting hospice, healthcare fraud in CA

Federal authorities carried out 'Operation Never Say Die' in Southern California, arresting multiple people in a crackdown on sham hospice providers; officials say the scheme and related fraudsters stole over $50 million from Medicare, with two defendants accused of bilking more than $7 million. HHS and investigative sources claim California's Medicaid fraud may be ~25% (~$50 billion of a ~$200 billion state Medicaid budget) and 221 hospice providers in LA have been suspended; DOJ officials indicate this enforcement may presage more charges and indictments.

Analysis

Enforcement shocks in one state accelerate a multi-year re-pricing of hospice/home-health risk that has been largely off-consensus: expect a bifurcation between well-capitalized, compliance-focused operators and smaller, Medicaid-dependent chains. In the next 30–90 days we should see claims suspensions, targeted audits and payment freezes that temporarily depress reported revenue and raise operating leverage for providers with thin margins; by 6–18 months the main channel of damage will be higher SG&A for compliance and upward pressure on legal reserves.

Second-order supply effects matter: staffing vendors and revenue-cycle/analytics firms will see incremental demand as providers scramble to plug documentation gaps, while local capacity reductions from license suspensions will tighten labor markets and push hourly wages higher for home-health nurses—adding 150–300bps to labor cost for mid-size operators in stressed counties. State budget reactions are the critical macro lever: if policymakers opt for budget cuts or Medicaid rate resets within the next fiscal cycle, reimbursement compression will accelerate consolidation and create acquisition windows for strategic buyers.

The political/administrative risk is asymmetric and persistent — a sustained enforcement program raises tail risk of large clawbacks and contractual repudiations over 12–36 months, but a change in federal/state priorities could unwind some short-term pressure. Markets are likely to over-penalize visible hospice names first; that creates actionable dispersion where selective long exposure to high-quality providers and RCM/analytics vendors plus short exposure to Medicaid-exposed operators provides favorable risk-reward.

Key Decisions for Investors

• Pair trade (3–9 months): Short Amedisys (AMED) stock 1–2% NAV vs long UnitedHealth (UNH) 1% NAV. Rationale: AMED is more concentrated in hospice/home-health and faces near-term payment/audit risk; UNH is diversified with Optum risk-adjustment scale. Target 20–30% relative upside for the pair; stop-loss at 10% adverse move on the pair.
• Tactical long (6–12 months): Buy R1 RCM (RCM) or equivalent revenue-cycle/analytics providers, 1–2% NAV. Rationale: increased fraud scrutiny drives recurring demand for claims-validation and analytics, supporting multiple expansion. Expect 30–50% upside if adoption accelerates; principal risk is budget cuts reducing vendor spend—trim at 20% gains.
• Short Medicaid-concentrated insurers (3–12 months): Buy puts on Centene (CNC) or Molina (MOH) sized to 1% NAV or underweight in portfolios. Rationale: state-level Medi-Cal reactions and clawback risk concentrate losses here. Risk/reward: expect 15–35% downside in adverse scenarios; hedge with broad-market protection given political event risk.
• Opportunistic long (6–18 months): Accumulate high-quality, balance-sheet strong home-health/hospice names (e.g., Chemed CHE) on headline-driven selloffs, 0.5–1.5% NAV. Rationale: clean operators win consolidation and command takeover premiums. Target 25–40% upside; keep a 12–18 month horizon and use earnings windows as add points.